Chemotherapy for PR Positive Breast Cancer: 87 Real Stories

87 stories match breast cancer, PR positive and chemotherapy. 81 of them mention surgery.

Cancer Stories

Allison, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient Story
OutcomeCare Ongoing
Dorian, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Dorian's Survivor Story

Patient Info: Dorian de Salvo, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of March 2024, Dorian had a complete response to TCHP chemotherapy, clear surgical margins, and no lymph-node involvement after surgery, with radiation completed and additional care still expected for several months.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic hormone receptor-positive breast cancer with paraneoplastic eosinophilic fasciitis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive; PR-positive; eosinophilia during paraneoplastic eosinophilic fasciitis flare

Metastatic Site: pelvis

As of February 2024, paraneoplastic eosinophilic fasciitis had remitted after prednisone plus systemic breast-cancer therapy, and 6-month follow-up showed no further skin recurrence or cancer progression.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Male Invasive Lobular Breast Cancer With a Pathogenic PALB2 Variant

Patient Info: Anonymized, male, 40s

Biomarkers: ER-positive; PR-positive; HER2 not amplified; pathogenic PALB2 variant

He was disease-free at 1-year follow-up after mastectomy, chemotherapy, and radiotherapy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

Five Years Without Breast Cancer Recurrence Despite a Markedly Elevated CA 15-3

Patient Info: Anonymized, female, 70+ | Stage I

Biomarkers: ER-positive, PR-positive, HER2-positive

Five years after her Stage I breast-cancer diagnosis, breast imaging and systemic evaluation showed no evidence of recurrence. The markedly elevated CA 15-3 was traced to a separate renal tumor and normalized after nephrectomy.

PubMed Central
OutcomeCancer-Free / NED
Susan, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Susan's Patient Story

Patient Info: Susan, Female, 70+

Biomarkers: BRCA negative; earlier breast cancer described as triple-negative; later breast cancer estrogen-positive and progesterone-positive; HER2 not reported

As of August 2023, Susan was living after multiple breast cancer diagnoses, including a later estrogen-positive/progesterone-positive non-metastatic breast cancer treated with bilateral mastectomy and ongoing 5-year estrogen-blocker therapy.

The Patient Story
OutcomeCare Ongoing
Susan, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Susan's Survivor Story

Patient Info: Susan, Female, 70+

Biomarkers: 2021 breast cancer described as estrogen-positive and progesterone-positive; HER2 not reported. First breast cancer biomarker status not reported.

As of August 2023, Susan was living in survivorship after a first breast cancer treated with lumpectomy, chemotherapy, and radiation and a later separate breast cancer treated with bilateral mastectomy.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Megan, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Megan's Survivor Story

Patient Info: Megan Claire Chase, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2 not reported

As of July 2023, Megan-Claire was in survivorship after Stage II invasive lobular breast cancer, with clear early scans but significant long-term effects, surgical menopause, chronic pain, fatigue, chemo brain, and inability to tolerate recurrence-prevention medications.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Sarah, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III HR-Positive Breast Cancer: Sarah's Survivor Story

Patient Info: Sarah McDonald, Female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

Sarah was 10 years from diagnosis without a recurrence and described the breast cancer as successfully treated. She later paused hormone therapy, completed IVF and gave birth at age 48.

The Patient Story
OutcomeCancer-Free / Long-Term Survivor
Abigail, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Abigail's Patient Story

Patient Info: Abigail Myers, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: bones, brain

Abigail continued living with Stage IV metastatic breast cancer after about 8 years of multiple treatment lines, including therapy for bone and brain metastases.

Dana-Farber
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Chemotherapy complication: methotrexate absorbed into the bloodstream after spinal injection

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; Oncotype DX Recurrence Score 20

Metastatic Site: leptomeninges / central nervous system; brain

Five months after leptomeningeal carcinomatosis was recognised, she developed a new 2 cm brain lesion and neurological decline. Her family chose supportive care, and she died 10 days after transfer to inpatient hospice.

PubMed Central
OutcomeIn Memory
Becki, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Becki's Patient Story

Patient Info: Becki, Female, 40s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of 2023, Becki was receiving ongoing treatment for Stage II triple-positive breast cancer after recently completing mastectomy and experiencing chemotherapy-related fatigue, hair loss, and chemo fog.

Our Cancer Stories
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast Cancer Spread to the Sinuses, Eye Sockets and Skull

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive

Metastatic Site: ethmoid and frontal sinuses; both orbits; multiple…

At 1-year follow-up, the sino-orbital metastases had not progressed on neuroimaging, right-eye visual acuity remained good, and chemoradiotherapy had been tolerated without complication.

PubMed Central
OutcomeStable Disease / Care Ongoing
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Recurrent Lobular Breast Cancer Spread to the Opposite Armpit Lymph Node

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: Contralateral right axillary lymph node

After surgery for the recurrence and removal of the opposite-side axillary nodes, the patient proceeded with adjuvant chemotherapy and remained in active treatment.

PubMed Central
OutcomeCare Ongoing
Jeanine, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Jeanine's Patient Story

Patient Info: Jeanine, Female | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; genetic testing negative

Jeanine completed chemotherapy, bilateral mastectomy, and post-surgery radiation after her disease was restaged from Stage II to Stage III, and she described continued active oncology care and advocacy as of June 2021.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
MB
Breast Cancer

Male breast cancer discovered after years of stiff-person syndrome

Patient Info: Anonymized, Male, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative; anti-amphiphysin antibody positive at 1:64; hereditary cancer panel negative for pathogenic germline variants.

He completed curative-intent breast cancer treatment and reported substantial improvement in upper-body stiffness, although lower-extremity stiffness, cramps, and unsteadiness persisted.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast cancer recurrence in the mandibular condyle causing jaw pain

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative.

Metastatic Site: right mandibular condyle with extension into the…

After anastrozole and 60 Gy of radiation, her jaw pain, mouth opening, and function improved, although some discomfort remained and palliative systemic treatment was continuing.

PubMed Central
OutcomeResponding Well
LA
Breast Cancer

Locally advanced male breast cancer associated with a pathogenic ATM variant

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: ER 100% positive; PR 100% positive; HER2-negative; Ki-67 30%; germline pathogenic ATM variant c.2921+1G>A.

Two years after diagnosis, he had an ECOG performance status of 0 and remained without signs of breast-cancer relapse or another primary cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

A New Breast Cancer Arising Beneath an Accessory Nipple

Patient Info: Anonymized, Female, 40s

Biomarkers: ER 5%; PR 5–10%; HER2-negative.

After chemotherapy, surgery, endocrine therapy, proton radiation, and later reconstruction revision, she was currently without evidence of disease.

PubMed Central
OutcomeCancer-Free / NED